A. In a patient with T2D and ASCVD B. At the time of diagnosis of T2D in a patient with clinical ASCVD C. In all patients at the time of diagnosis of T2D D. At hospital discharge after admission for an ASCVD event E. Unsure

A. Age older than 35 years with coronary stenosis B. Age older than 35 years with evidence of lower extremity artery stenosis of at least 50% C. Age older than 55 years alone D. Age older than 55 years with evidence of lower extremity artery stenosis of at least 50% E. Unsure

A. Sodium-glucose co-transporter 2 (SGLT-2) inhibitor B. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) C. Sulfonylurea D. Thiazolidinedione E. Unsure

A. When there is a compelling need to minimize weight gain or promote weight loss B. When there is a compelling need to minimize hypoglycemia C. When there is a compelling need to decrease cardiovascular risk in patients with established atherosclerotic cardiovascular disease (ASCVD) D. When drug cost is a major consideration E. Unsure

A. Basal insulin B. Rapid-acting insulin C. Injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) D. Premix insulin product E. Unsure

A. Stimulation of glucose-dependent insulin secretion B. Suppression of glucagon release from pancreatic α-cells C. Delayed gastric emptying D. All of the above E. Unsure

A. Exenatide B. Liraglutide C. Injectable semaglutide D. Dulaglutide E. Unsure

A. 30 units B. 40 units C. 50 units D. 60 units E. Unsure

A. Exenatide XR B. Liraglutide C. Lixisenatide D. Exenatide twice-daily E. Unsure

A. It can be taken orally any time of day without regard to meals B. It should be taken with at least 4 ounces of fluid C. For patients with swallowing difficulties, it can be crushed and mixed with applesauce D. It should be taken at least 30 minutes before the first food, beverage, or other oral medication of the day E. Unsure